cakmak, Ender ozgunBayam, EmrahYilmaz, FatihKahyaoglu, Muzaffercelik, Mehmetocal, LutfiIzgi, Ibrahim Akin2025-05-102025-05-1020210003-31971940-157410.1177/0003319721991378https://doi.org/10.1177/0003319721991378https://hdl.handle.net/20.500.14720/7242Ocal, Lutfi/0000-0003-4059-0861; Celik, Mehmet/0000-0003-0364-2239; Cakmak, Ender Ozgun/0000-0001-6767-6935We report the results of endovascular treatment of Trans-Atlantic Inter-Society Consensus II (TASC) A&B, TASC C, and TASC D aortoiliac lesions in a single vascular center. In this retrospective, observational cohort study, we analyzed 395 patients (mean age 61.2 +/- 9.0; 359 men) between January 2015 and December 2017. Technical success was achieved in 96.5%; in-hospital mortality was 1.2% (n = 5). Median follow-up was 36 months (range 24-49 months). After 1 and 5 years, the primary patency rates were 99% and 85% for TASC A&B, 90%, and 78% for TASC C, and 90% and 74% for TASC D. Secondary patency rates were 99% and 90% for TASC A&B, 98% and 65% for TASC C, and 97% and 65% for TASC D. Previous peripheral revascularization (hazard ratio: 1.76, 95% CI: 1.01-3.08, P = .04) was associated with decreased primary patency along with lower age, TASC C, and TASC D class. This analysis reported the acceptable effectiveness and safety of stenting for all types of aortoiliac occlusive disease in a modern setting, with few complications and excellent long-term primary and secondary patency rates.eninfo:eu-repo/semantics/closedAccessAortoiliac Occlusive DiseaseIliac ArteryPrimary PatencyStentTasc C And D LesionsArticle727Q3Q264065033541091WOS:000637152800001